Barclays keeps Buy rating on Collegium Pharmaceutical
Alpha Vantage · Moomoo · · AI-summarised by FinFlash
Barclays reiterated its Buy rating on Collegium Pharmaceutical (COLL.US) and kept its target price at $48, signalling continued confidence in the stock's performance. The repeat call leaves the brokerage's view unchanged rather than reflecting a new upgrade. For investors, the maintained target implies Barclays still sees upside in Collegium shares.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.